Open AccessReactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
Author(s) -
Alyson Kaplan,
Elliott DeHaan,
Charles Maltz
Publication year - 2021
Publication title -
acg case reports journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 4
ISSN - 2326-3253
DOI - 10.14309/crj.0000000000000594
Subject(s) - medicine , virology , human immunodeficiency virus (hiv) , multiple drug resistance , hepatitis b virus , drug resistance , hepatitis b , hepatitis c virus , drug , hepatitis c , immunology , virus , pharmacology , microbiology and biotechnology , biology
Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.